De novo donor HLA-specific antibodies after heart transplantation are an independent predictor of poor patient survival

American Journal of Transplantation

Volumn 11, Issue 2, 2011, Pages 312-319

  Smith, J D ^a   Banner, N R ^a   Hamour, I M ^a   Ozawa, M ^b   Goh, A ^b   Robinson, D ^c   Terasaki, P I ^b   Rose, M L ^a  

^a HAREFIELD HOSPITAL   (United Kingdom)

^b TERASAKI FOUNDATION LABORATORY   (United States)

^c UNIVERSITY OF SUSSEX   (United Kingdom)

Author keywords

Donor specific HLA antibodies; heart transplantation

Indexed keywords

HLA ANTIBODY; HLA DR ANTIGEN;

ADULT; AGE DISTRIBUTION; ANTIBODY PRODUCTION; ARTICLE; CARDIAC GRAFT REJECTION; CAUSE OF DEATH; CONTROLLED STUDY; FEMALE; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; ORGAN DONOR; PATIENT MONITORING; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL RATE;

ADULT; ANTIBODY SPECIFICITY; COMPLEMENT FIXATION TESTS; FEMALE; GRAFT REJECTION; HEART TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HLA-DR ANTIGENS; HUMANS; ISOANTIBODIES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; TISSUE DONORS;

EID: 79551472638     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2010.03383.x     Document Type: Article

References (33)

1. Smith JD, Danskine AJ, Laylor RM, Rose ML, Yacoub MH,. The effect of panel reactive antibodies and the donor specific crossmatch on graft survival after heart and heart-lung transplantation. Transpl Immunol 1993; 1: 60-65.
2. Smith JD, Hamour IM, Banner NR, Rose ML,. C4d fixing, luminex binding antibodies-a new tool for prediction of graft failure after heart transplantation. Am J Transplant 2007; 7: 2809-2815.
3. Przybylowski P, Balogna M, Radovancevic B, et al,. The role of flow cytometry-detected IgG and IgM anti-donor antibodies in cardiac allograft recipients. Transplantation 1999; 67: 258-262.
4. Tambur AR, Bray RA, Takemoto SK, et al,. Flow cytometric detection of HLA-specific antibodies as a predictor of heart allograft rejection. Transplantation 2000; 70: 1055-1059.
5. Stastny P, Lavingia B, Fixler DE, Yancy CW, Ring WS,. Antibodies against donor human leukocyte antigens and the outcome of cardiac allografts in adults and children. Transplantation 2007; 84: 738-745.
6. Kaczmarek I, Deutsch MA, Kauke T, et al,. Donor-specific HLA alloantibodies: Long-term impact on cardiac allograft vasculopathy and mortality after heart transplant. Exp Clin Transplant 2008; 6: 229-235.
7. Tambur AR, Pamboukian SV, Costanzo MR, et al,. The presence of HLA-directed antibodies after heart transplantation is associated with poor allograft outcome. Transplantation 2005; 80: 1019-1025.
8. Ho EK, Vlad G, Colovai AI, et al,. Alloantibodies in heart transplantation. Hum Immunol 2009; 70: 825-829.
9. Tait BD,. Solid phase assays for HLA antibody detection in clinical transplantation. Curr Opin Immunol 2009; 21: 573-577.
10. Tait BD, Hudson F, Cantwell L, et al,. Review article: Luminex technology for HLA antibody detection in organ transplantation. Nephrology (Carlton) 2009; 14: 247-254.
11. Bray RA, Gebel HM,. Strategies for human leukocyte antigen antibody detection. Curr Opin Organ Transplant 2009; 14: 392-397.
12. Lachmann N, Terasaki PI, Budde K, et al,. Anti-human leukocyte antigen and donor-specific antibodies detected by luminex post-transplant serve as biomarkers for chronic rejection of renal allografts. Transplantation 2009; 87: 1505-1513.
13. Lee PC, Zhu L, Terasaki PI, Everly MJ,. HLA-specific antibodies developed in the first year post-transplant are predictive of chronic rejection and renal graft loss. Transplantation 2009; 88: 568-574.
14. Zeevi A, Lunz JG3, Shapiro R, et al,. Emerging role of donor-specific anti-human leukocyte antigen antibody determination for clinical management after solid organ transplantation. Hum Immunol 2009; 70: 645-650.
15. Everly MJ, Everly JJ, Arend LJ, et al,. Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss. Am J Transplant 2009; 9: 1063-1071.
16. Costanzo MR, Naftel DC, Pritzker MR, et al,. Heart transplant coronary artery disease detected by coronary angiography: A multiinstitutional study of preoperative donor and recipient risk factors. Cardiac Transplant Research Database. J Heart Lung Transplant 1998; 17: 744-753.
17. Kobashigawa J, Wener L, Johnson J, et al,. Longitudinal study of vascular remodeling in coronary arteries after heart transplantation. J Heart Lung Transplant 2000; 19: 546-550.
18. Valantine H,. Cardiac allograft vasculopathy after heart transplantation: Risk factors and management. J Heart Lung Transplant 2004; 23 (5 Suppl): S187-S193
19. Vassalli G, Gallino A, Weis M, et al,. Alloimmunity and nonimmunologic risk factors in cardiac allograft vasculopathy. Eur Heart J 2003; 24: 1180-1188.
20. Hamour IM, Lyster HS, Burke MM, Rose ML, Banner NR,. Mycophenolate mofetil may allow cyclosporine and steroid sparing in de novo heart transplant patients. Transplantation 2007; 83: 570-576.
21. Stewart S, Winters GL, Fishbein MC, et al,. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant 2005; 24: 1710-1720.
22. Morales-Buenrostro LE, Terasaki PI, Marino-Vazquez LA, Lee JH, El-Awar N, Alberu J,. "Natural" human leukocyte antigen antibodies found in nonalloimmunized healthy males. Transplantation 2008; 86: 1111-1115.
23. Taylor DO, Edwards LB, Aurora P, et al,. Registry of the International Society for Heart and Lung Transplantation: Twenty-fifth official adult heart transplant report-2008. J Heart Lung Transplant 2008; 27: 943-956.
24. Suitters A, Rose M, Higgins A, Yacoub MH,. MHC antigen expression in sequential biopsies from cardiac transplant patients-correlation with rejection. Clin Exp Immunol 1987; 69: 575-583.
25. Labarrere CA, McIntyre JA, Halbrook H, Faulk WP,. Major histocompatibility antigens in transplanted human hearts before perfusion. J Heart Lung Transplant 1991; 10: 409-415.
26. Rose ML, Gracie JA, Fraser A, Chisholm PM, Yacoub MH,. Use of monoclonal antibodies to quantitate T lymphocyte subpopulations in human cardiac allografts. Transplantation 1984; 38: 230-234.
27. Page C, Rose M, Yacoub M, Pigott R,. Antigenic heterogeneity of vascular endothelium. Am J Pathol 1992; 141: 673-683.
28. Peng S, Kim TW, Lee JH, et al,. Vaccination with dendritic cells transfected with BAK and BAX siRNA enhances antigen-specific immune responses by prolonging dendritic cell life. Hum Gene Ther 2005; 16: 584-593.
29. Harris PE, Bian H, Reed EF,. Induction of high affinity fibroblast growth factor receptor expression and proliferation in human endothelial cells by anti-HLA antibodies: A possible mechanism for transplant atherosclerosis. J Immunol 1997; 159: 5697-5704.
30. Jindra PT, Zhang X, Mulder A, et al,. Anti-HLA antibodies can induce endothelial cell survival or proliferation depending on their concentration. Transplantation 2006; 82: S33-S35.
31. Yamakuchi M, Kirkiles-Smith NC, Ferlito M, et al,. Antibody to human leukocyte antigen triggers endothelial exocytosis. Proc Natl Acad Sci U S A 2007; 104: 1301-1306.
32. Rahimi S, Qian Z, Layton J, Fox-Talbot K, Baldwin WM, III, Wasowska BA,. Non-complement- and complement-activating antibodies synergize to cause rejection of cardiac allografts. Am J Transplant 2004; 4: 326-334.
33. Everly MJ, Terasaki PI,. Monitoring and treating post-transplant human leukocyte antigen antibodies. Hum Immunol 2009; 70: 655-659.